Header Logo

Connection

LEO LUZNIK to Young Adult

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Young Adult.
LEO LUZNIK
Connection Strength
0.550
Young Adult
  1. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022 01 27; 139(4):608-623.
    View in: PubMed
    Score: 0.055
  2. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
    View in: PubMed
    Score: 0.055
  3. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2019 06; 25(6):1128-1135.
    View in: PubMed
    Score: 0.045
  4. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018 02; 24(2):343-352.
    View in: PubMed
    Score: 0.041
  5. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
    View in: PubMed
    Score: 0.038
  6. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
    View in: PubMed
    Score: 0.036
  7. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11; 124(25):3817-27.
    View in: PubMed
    Score: 0.033
  8. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22; 115(16):3224-30.
    View in: PubMed
    Score: 0.024
  9. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023 06 22; 141(25):3031-3038.
    View in: PubMed
    Score: 0.015
  10. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 06 20; 39(18):1971-1982.
    View in: PubMed
    Score: 0.013
  11. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020 08 25; 4(16):3913-3925.
    View in: PubMed
    Score: 0.013
  12. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia. 2020 06; 34(6):1563-1576.
    View in: PubMed
    Score: 0.012
  13. Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. J Immunother. 2019 04; 42(3):73-80.
    View in: PubMed
    Score: 0.011
  14. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019 Apr; 6(4):e183-e193.
    View in: PubMed
    Score: 0.011
  15. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1022-1028.
    View in: PubMed
    Score: 0.010
  16. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 06; 24(6):1274-1280.
    View in: PubMed
    Score: 0.010
  17. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018 01 11; 131(2):247-262.
    View in: PubMed
    Score: 0.010
  18. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1887-1894.
    View in: PubMed
    Score: 0.010
  19. Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2017 Apr; 23(4):612-617.
    View in: PubMed
    Score: 0.010
  20. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
    View in: PubMed
    Score: 0.010
  21. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan; 22(1):112-8.
    View in: PubMed
    Score: 0.009
  22. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
    View in: PubMed
    Score: 0.009
  23. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
    View in: PubMed
    Score: 0.009
  24. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1514-7.
    View in: PubMed
    Score: 0.008
  25. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
    View in: PubMed
    Score: 0.007
  26. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
    View in: PubMed
    Score: 0.007
  27. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma. 2011 Nov; 52(11):2076-81.
    View in: PubMed
    Score: 0.007
  28. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1404-9.
    View in: PubMed
    Score: 0.006
  29. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2011 Jan 13; 117(2):608-17.
    View in: PubMed
    Score: 0.006
  30. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
    View in: PubMed
    Score: 0.006
  31. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18; 115(11):2136-41.
    View in: PubMed
    Score: 0.006
  32. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun; 43(12):969-70.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.